Back to Search
Start Over
Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells.
- Source :
-
OncoTargets & Therapy . Mar2019, Vol. 12, p2187-2191. 5p. - Publication Year :
- 2019
-
Abstract
- Background: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission. Methods: We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells. Results: At ~6 weeks after treatment, repeated bone marrow smear and flow cytometry analysis revealed no lymphoblasts. Conclusion: Our results suggest that sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells is a valuable option for relapsed patients with prior infusion of murine-derived, CD19-directed CAR-T cells. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LYMPHOBLASTIC leukemia
*ACUTE leukemia
*BONE marrow
*CELLS
Subjects
Details
- Language :
- English
- ISSN :
- 11786930
- Volume :
- 12
- Database :
- Academic Search Index
- Journal :
- OncoTargets & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 135798590
- Full Text :
- https://doi.org/10.2147/OTT.S189103